TLR4 and epilepsy: Therapies interfering with HMGB1/TLR4, NF-κB, IL-1β, COX-2, PGE2/EP2, and TGF-β signaling pathways, and other inflammatory targets have been proposed to treat epilepsy [7,218,221,254].